acetylcysteine and aromasil

acetylcysteine has been researched along with aromasil in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Al Mamun Bhuyan, A; Bissinger, R; Cao, H; Lang, F1
Briganti, S; Camera, E; Galati, R; Mastrofrancesco, A; Nuvoli, B1

Reviews

1 review(s) available for acetylcysteine and aromasil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for acetylcysteine and aromasil

ArticleYear
Triggering of Suicidal Erythrocyte Death by Exemestane.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:1

    Topics: Acetylcysteine; Androstadienes; Aniline Compounds; Calcium; Cell Size; Cells, Cultured; Ceramides; Eryptosis; Erythrocytes; Flow Cytometry; Humans; Imidazoles; Immunoassay; Oxidative Stress; Phosphatidylserines; Pyridines; Reactive Oxygen Species; Xanthenes

2017
Modulation of reactive oxygen species via ERK and STAT3 dependent signalling are involved in the response of mesothelioma cells to exemestane.
    Free radical biology & medicine, 2018, 02-01, Volume: 115

    Topics: Acetylcysteine; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Asbestos; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Environmental Exposure; Extracellular Signal-Regulated MAP Kinases; Humans; Mesothelioma; Oxidative Stress; Pleural Neoplasms; Reactive Oxygen Species; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; STAT3 Transcription Factor; Treatment Outcome

2018